Supplementary
Supplementary Table 1. ICD-10- and ATC-codes used to define drug and comorbidity.

	Coding system	Codes
Current drug use ¹		
Antihypertensive drugs	ATC	C03A C07 C08 C09
ACE/ARBs	ATC	C09
Calcium channel blockers	ATC	C08
Beta-blockers	ATC	C07
Thiazides	ATC	C03A
Loop-diuretics	ATC	C03C
Glucose-lowering drugs	ATC	A10A A10B
Non-insulin glucose lowering	ATC	A10B
drugs		
Insulin	ATC	A10A
Insulin monotherapy	ATC	A10A, not A10B
Antiplatelets	ATC	B01AC
Anticoagulant therapy	ATC	B01AA, B01AE07, B01AF
Opioids	ATC	N02A
Benzodiazepines and derivates	ATC	N05BA N05CD-F
Antipsychotics	ATC	N05AA N05AB N05AC N05AD N05AE
F		N05AF N05AG N05AH N05AX N05AL01
		N05AL05
Antidepressants	ATC	N06A
Systemic glucocorticoids	ATC	H02AB
Inhaled corticosteroids	ATC	R03AK R03AL R03BA
Lipid modifying agents	ATC	C10
NSAIDs	ATC	M01A (excluding M01AX)
Methotrexate	ATC	L04AX03
Biologics	SKS	ВОНЈ16А ВОНЈ18А1-5 ВОНЈ18В1-8
0		ВОНЈ18С1 ВОНЈ19Н4 ВОНЈ19Н6 ВОНЈ26
		BWHB84
	ATC	L04AA21 L04AA23-6 L04AA28 L04AA33
		L04AA34 L04AA36 L04AB01 L04AB02
		L04AB04 L04AB05 L04AC02 L04AC03
		L04AC05 L04AC07 L04AC08 L04AC10-4
		L04AC16 L04AC17
		D11AH05 L01XC02
Medical history ²		
Chronic lung disease	ICD-10	J41-J47
	ATC	R03AK, R03AL, R03BA, R03AC12, R03AC13
		R03AC18, R03AC19, R03CC12, R03BB04,
		R03BB05, R03BB06, R03BB07
Hypertension	ICD-10	I10 I11 I12 I13 I15

	ATC	C08, C03A, C07, C09
Ischemic heart disease	ICD-10	I20 I21 I22 I23 I24 I25
	ATC	N02BA C01DA B01AC24
Heart failure	ICD-10	I099A I110 I130 I132 I50
Atrial fibrillation	ICD-10	I48
Stroke	ICD-10	I60 I61 I62 I63 I64 I69
Diabetes	ICD-10	E10 E11 E13 E14
	ATC	A10
Dementia	ICD-10	F00 F01 F02 F03 F1073 F1173 F1273 F1373
		F1473 F1573 F1673 F1873 F1973
	ATC	N06D
Any cancer	ICD-10	C00-C97, excluding C44
Chronic liver disease	ICD-10	K700-K704 K709 K71-K74 K760 K766 B150
		B160 B162 B18 B190 I85
Hospital-diagnosed kidney	ICD-10	I12 I13 N00-N05 N07 N08 N11 N14 N18 N19
disease		E102 E112 E142
Alcohol abuse	ICD-10	F10 E244 G312 G621 G721 I426 K292 K70
		K852 K860 Q860 Z502 Z714 Z721
	ATC	N07BB
Substance abuse	ICD-10	F11-F19
	ATC	N07BC
Organ transplantation	ICD-10	Z94
Overweight and obesity	ICD-10	E66
	ATC	A08
Severe mental illness	ICD-10	F20 F25 F30 F31
(schizophrenia, schizoaffective		
disorder, or bipolar disorder)		
	ATC	N05AN

¹Current drug use is defined as at least one filled prescription within 6 months prior to the test date. Of note, there is a lag of 15 days on prescription data.

ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; NSAID: non-steroidal anti-inflammatory drugs.

²Medical history is based on an ever-recording of hospital discharge diagnoses, with or without combination with drug redemption data.

Supplementary Table 2. Baseline characteristics for SARS-CoV-2 PCR positive cases with a fatal course within 30 days, stratified by whether

cases were managed in the community or hospitalized prior to their death.

•	SARS-CoV-2 PCR positive cases with fatal course				
		A	All	Hosp	italized
Characteristic	All N=524 (100%)	Community- managed** N=115 (22%)	Hospitalized N=409 (78%)	Non-ICU admission N=330 (63%)	ICU admission N=79 (15%)
Age years, median (IQR)	82 (75-89)	87 (79-92)	81 (74-87)	82 (75-88)	73 (68-77)
0-29	0 (-)***	0 (-)***	0 (-)***	0 (-)***	0 (-)***
30-59	15 (2.9%)***	(n<5)***	_***	_***	6 (7.6%)***
60-69	51 (9.7%)	6 (5.2%)	45 (11%)	27 (8.2%)	18 (23%)
70-79	149 (28%)	22 (19%)	127 (31%)	86 (26%)	41 (52%)
80-89	197 (38%)	42 (37%)	155 (38%)	141 (43%)	14 (18%)
90+	112 (21%)	44 (38%)	68 (17%)	68 (21%)	0 (-)
Sex					
Female	225 (43%)	67 (58%)	158 (39%)	146 (44%)	12 (15%)
Male	299 (57%)	48 (42%)	251 (61%)	184 (56%)	67 (85%)
Authorized health care workers	(n<5)	0 (-)	(n<5)	0 (-)	$(n \le 5)$
Nurse	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
Physician	(n<5)	0 (-)	$(n \le 5)$	0 (-)	$(n \le 5)$
Other	(n<5)	0 (-)	$(n \le 5)$	0 (-)	$(n \le 5)$
Number of comorbidities ¹					
Median [IQR]	3 (2-4)	3 (2-4)	3 (2-4)	3 (2-5)	3 (1-4)
0	24 (4.6%)	8 (7.0%)	16 (3.9%)	11 (3.3%)	5 (6.3%)
1	75 (14%)	20 (17%)	55 (13%)	39 (12%)	16 (20%)
2	103 (20%)	27 (23%)	76 (19%)	58 (18%)	18 (23%)
3	114 (22%)	22 (19%)	92 (22%)	73 (22%)	19 (24%)
4+	208 (40%)	38 (33%)	170 (42%)	149 (45%)	21 (27%)
Hospital contacts within the last year ²					
Median [IQR]	1 (0-2)	0 (0-1)	1 (0-2)	1 (0-2)	0 (0-1)
0	252 (48%)	61 (53%)	191 (47%)	143 (43%)	48 (61%)
1	136 (26%)	32 (28%)	104 (25%)	88 (27%)	16 (20%)

2	59 (11%)	11 (9.6%)	48 (12%)	40 (12%)	8 (10%)
3	37 (7.1%)	7 (6.1%)	30 (7.3%)	-	(n<5)
4+	40 (7.6%)	(n<5)	-	-	5 (6.3%)
Current drug use ³					
Antihypertensive drugs	317 (60%)	53 (46%)	264 (65%)	216 (65%)	48 (61%)
ACE/ARBs	187 (36%)	26 (23%)	161 (39%)	128 (39%)	33 (42%)
Calcium channel blockers	94 (18%)	10 (8.7%)	84 (21%)	70 (21%)	14 (18%)
Beta-blockers	166 (32%)	26 (23%)	140 (34%)	116 (35%)	24 (30%)
Thiazides	49 (9.4%)	12 (10%)	37 (9.0%)	29 (8.8%)	8 (10%)
Loop-diuretics	174 (33%)	35 (30%)	139 (34%)	121 (37%)	18 (23%)
Glucose-lowering drugs	101 (19%)	13 (11%)	88 (22%)	69 (21%)	19 (24%)
Non-insulin glucose lowering drugs	82 (16%)	8 (7.0%)	74 (18%)	57 (17%)	17 (22%)
Insulin	55 (10%)	8 (7.0%)	47 (11%)	40 (12%)	7 (8.9%)
Insulin monotherapy	19 (3.6%)	5 (4.3%)	14 (3.4%)	-	$(n \le 5)$
Antiplatelets	180 (34%)	31 (27%)	149 (36%)	120 (36%)	29 (37%)
Anticoagulant therapy	147 (28%)	31 (27%)	116 (28%)	101 (31%)	15 (19%)
Opioids	187 (36%)	51 (44%)	136 (33%)	120 (36%)	16 (20%)
Benzodiazepines and derivates	103 (20%)	27 (23%)	76 (19%)	68 (21%)	8 (10%)
Antipsychotics	63 (12%)	22 (19%)	41 (10%)	-	$(n \le 5)$
Antidepressants	155 (30%)	49 (43%)	106 (26%)	93 (28%)	13 (16%)
Systemic glucocorticoids	71 (14%)	15 (13%)	56 (14%)	50 (15%)	6 (7.6%)
Inhaled corticosteroids	83 (16%)	13 (11%)	70 (17%)	60 (18%)	10 (13%)
Leukotriene receptor antagonist	(n<5)	(n<5)	(n<5)	(n<5)	$(n \le 5)$
Lipid modifying agents	174 (33%)	25 (22%)	149 (36%)	115 (35%)	34 (43%)
NSAID	50 (9.5%)	(n<5)	-	-	16 (20%)
Methotrexate	5 (1.0%)	0 (-)	5 (1.2%)	(n<5)	(n<5)
Biologics	(n<5)	0 (-)	(n<5)	(n<5)	0 (-)
Medical history ⁴					
Chronic lung diseases*	143 (27%)	22 (19%)	121 (30%)	99 (30%)	22 (28%)
Hypertension*	378 (72%)	75 (65%)	303 (74%)	253 (77%)	50 (63%)
Ischemic heart disease*	157 (30%)	33 (29%)	124 (30%)	101 (31%)	23 (29%)
Heart failure	98 (19%)	18 (16%)	80 (20%)	73 (22%)	7 (8.9%)

Atrial fibrillation	157 (30%)	38 (33%)	119 (29%)	107 (32%)	12 (15%)
Stroke	126 (24%)	31 (27%)	95 (23%)	87 (26%)	8 (10%)
Diabetes*	134 (26%)	21 (18%)	113 (28%)	90 (27%)	23 (29%)
Dementia*	112 (21%)	41 (36%)	71 (17%)	71 (22%)	0 (-)
Any cancer	128 (24%)	22 (19%)	106 (26%)	87 (26%)	19 (24%)
Chronic liver disease	14 (2.7%)	0 (-)	14 (3.4%)	-	(n<5)
Hospital-diagnosed kidney disease	74 (14%)	9 (7.8%)	65 (16%)	56 (17%)	9 (11%)
Alcohol abuse*	33 (6.3%)	(n<5)	-	-	6 (7.6%)
Substance abuse*	19 (3.6%)	(n<5)	-	-	(n<5)
Major psychiatric disorder	12 (2.3%)	(n<5)	-	-	(n<5)
Organ transplantation	6 (1.1%)	0 (-)	6 (1.5%)	(n<5)	(n<5)
Overweight and obesity*	53 (10%)	7 (6.1%)	46 (11%)	36 (11%)	10 (13%)
Rheumatoid arthritis/connective tissue	48 (9.2%)	9 (7.8%)	39 (9.5%)	32 (9.7%)	7 (8.9%)
disease					

¹Number of comorbidities is the total number of coexisting conditions listed under `Medical history'.

IQR: interquartile range; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2. ICU: intensive care unit; ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; NSAID: non-steroidal anti-inflammatory drugs.

²Hospital admissions of more than 12 hours, from 365 days to 14 days prior to the index date.

³Current drug use is defined as at least one filled prescription within 6 months prior to the test date. Of note, there is a lag of 15 days on prescription data.

⁴Medical history is based on an ever-recording of hospital discharge diagnoses. Comorbidities marked by * are defined by hospital discharge diagnoses in combination with drug use for the comorbidity (i.e. filled prescription within 6 months prior to the test date). For details on definitions, see **Supplementary Table 1**.

^{**} These patients died without having a recorded hospital admission (defined as hospitalizations lasting 12 hours or more) within 14 days of the index date. Of note, 15 of these patients were recorded as being admitted to hospital at time of death (mainly due to death occurring very shortly after admission).

^{***}Age categories (0-29, 30-59) collapsed to ensure anonymity.

Supplementary Table 3. Predictors of hospitalization and having a fatal course within 30 days among SARS-CoV-2 PCR positive cases, when adjusting single comorbidities for

age-, sex-, and additionally for total number of comorbidities.

	Hospitalization	Death within 30 days ²
Characteristic	Age-, sex., and number of comorbidities adjusted OR (95%CI)	Age-, sex., and number of comorbidities adjusted OR (95%CI)
Medical history ¹	comorbidities adjusted OK (5370C1)	comorbidities adjusted OK (9370CI)
Chronic lung diseases*	1.2 (1.0-1.4)	1.1 (0.9-1.4)
Hypertension*	1.0 (0.9-1.2)	0.7 (0.5-0.9)
Ischemic heart disease*	0.9 (0.7-1.1)	0.7 (0.6-1.0)
Heart failure	1.4 (1.1-1.9)	1.1 (0.8-1.5)
Loop-diuretics	1.8 (1.4-2.3)	1.5 (1.2-2.0)
Atrial fibrillation	0.9 (0.7-1.1)	1.1 (0.9-1.4)
Stroke	0.9 (0.7-1.1)	1.0 (0.8-1.3)
Diabetes*	1.2 (1.0-1.4)	1.1 (0.9-1.5)
Non-insulin glucose lowering drugs	1.2 (0.9-1.4)	1.0 (0.7-1.3)
Insulin	1.3 (1.0-1.8)	1.4 (1.0-2.0)
Insulin monotherapy	1.4 (0.9-2.2)	1.1 (0.6-2.0)
Dementia*	0.4 (0.3-0.5)	1.6 (1.2-2.1)
Any Cancer	1.0 (0.8-1.2)	1.0 (0.8-1.3)
Chronic liver disease	1.5 (1.1-2.2)	1.1 (0.6-2.1)
Hospital-diagnosed kidney disease	1.7 (1.3-2.3)	1.4 (1.0-2.0)
Alcohol abuse*	1.1 (0.8-1.5)	1.2 (0.8-1.9)
Substance abuse*	0.8 (0.6-1.2)	1.2 (0.7-2.2)
Major psychiatric disorder*	1.4 (0.8-2.5)	1.9 (0.9-3.9)
Benzodiazepines and derivates	1.5 (1.2-1.8)	1.8 (1.4-2.4)
Antipsychotics	1.1 (0.8-1.5)	3.2 (2.2-4.7)
Antidepressants	1.1 (0.9-1.3)	1.5 (1.2-1.9)
Organ transplantation	1.4 (0.7-2.8)	1.8 (0.7-4.8)
Overweight and obesity*	1.3 (1.0-1.6)	1.0 (0.7-1.4)
Rheumatoid arthritis/connective tissue disease	1.0 (0.8-1.3)	0.8 (0.6-1.2)

¹Medical history is based on an ever-recording of hospital discharge diagnoses. Comorbidities marked by * are defined by hospital discharge diagnoses in combination with drug redemptions (i.e. filled prescription within 6 months prior to the test date. Of note, there is a lag of 15 days on prescription data). For details on definitions, see **Supplementary Table 1**. ²Death was defined as all-cause mortality within 30 days from the index date.

OR: odds ratio; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

Supplementary Table 4. Clinical characteristics of SARS-CoV-2 PCR positive cases during subperiods

of the epidemic, i.e. containment phase, mitigation phase, and during reopening of the society.

	Containment phase ¹	Mitigation phase ²	During re-opening ³
	27th Feb to 11th Mar	12th Mar to 14th Apr	15th Apr onwards
All individuals tested (N)	2559	71631	144,968
PCR positive cases (N)	N=756	N=6,059	N=2,704
Age, median [IQR]	43 (32-50)	52 (38-66)	45 (29-61)
≤18 years	30 (4.0%)	183 (3.0%)	215 (8.0%)
19-59 years	671 (89%)	3,759 (62%)	1,734 (64%)
60-74 years	49 (6.5%)	1,155 (19%)	383 (14%)
≥75 years	6 (0.8%)	962 (16%)	372 (14%)
Sex			
Female	243 (32%)	3,598 (59%)	1,668 (62%)
Male	513 (68%)	2,461 (41%)	1,036 (38%)
Health care workers (N)	50 (6.6%)	1,482 (24%)	637 (24%)
Number of comorbidities	0 (0-1)	1 (0-2)	0 (0-1)
0	552 (73%)	2,929 (48%)	1,458 (54%)
1	160 (21%)	1,403 (23%)	598 (22%)
2	35 (4.6%)	705 (12%)	279 (10%)
3	0 (1 20/*	469 (7.7%)	155 (5.7%)
4+	9 (1.2%)*	553 (9.1%)	214 (7.9%)

¹Test strategy during the containment phase: mainly testing of suspected symptomatic COVID-19 cases with a relevant travel history (mainly from China and Italy)

²Test strategy during the mitigation phase: Initially testing of individuals with suspected COVID-19 requiring hospital admission, and testing of symptomatic frontline health care workers in critical functions (e.g. ICU personnel). From late-March onwards, upscaled to include testing of individuals with mild to moderate respiratory symptoms suspicious of COVID-19, as well as broader screening of healthcare professionals


³Test strategy during re-opening: Gradually upscaled to include testing of any individuals with mild to severe symptoms suspicious of COVID-19.

^{*}Number of comorbidities (3 and 4+) collapsed to ensure anonymity.


SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

Supplementary Figure 1. Hospitalization (A), ICU admission (B) and death in timely relation to the date of having a positive test for SARS-CoV-2 (C).


A) SARS-CoV-2 PCR positive cases who were hospitalized: date of hospital admission relative to sample date



B) SARS-CoV-2 PCR positive cases who were admitted to ICU: date of ICU admission relative to sample date



C) SARS-CoV-2 PCR positive cases who died: date of death relative to sample date



STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title	1
		or the abstract	
		(b) Provide in the abstract an informative and balanced summary of	2
		what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation	3
		being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	3
Setting	5	Describe the setting, locations, and relevant dates, including periods	3-5
O		of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and	4
•		methods of selection of participants. Describe methods of follow-up	Descriptive
		Case-control study—Give the eligibility criteria, and the sources and	study
		methods of case ascertainment and control selection. Give the	
		rationale for the choice of cases and controls	
		Cross-sectional study—Give the eligibility criteria, and the sources and	
		methods of selection of participants	
		(b) Cohort study—For matched studies, give matching criteria and	NA
		number of exposed and unexposed	
		Case-control study—For matched studies, give matching criteria and the	
		number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	4-5
		confounders, and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	4-5
measurement		methods of assessment (measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	3-5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	
		applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control	5
		for confounding	
		(b) Describe any methods used to examine subgroups and	NA
		interactions	
		(e) Explain how missing data were addressed	NA
		(d) Cohort study—If applicable, explain how loss to follow-up was	NA
		addressed	
		Case-control study—If applicable, explain how matching of cases and	
		controls was addressed	

Cross-sectional study—If applicable, describe analytical methods taking	
account of sampling strategy	
(e) Describe any sensitivity analyses	4-5

Continued on next page

-		•	
v	001	-14	-0
- 17	esi	111	

13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially	4
	eligible, examined for eligibility, confirmed eligible, included in the study, completing	
	follow-up, and analysed	
	(b) Give reasons for non-participation at each stage	
	(c) Consider use of a flow diagram	
14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and	5-7
	information on exposures and potential confounders	
	(b) Indicate number of participants with missing data for each variable of interest	
	(c) Cohort study—Summarise follow-up time (eg, average and total amount)	
15*	Cohort study—Report numbers of outcome events or summary measures over time	
	Case-control study—Report numbers in each exposure category, or summary measures of	
	exposure	
	Cross-sectional study—Report numbers of outcome events or summary measures	
16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their	5-7
	precision (eg, 95% confidence interval). Make clear which confounders were adjusted	
	for and why they were included	
	(b) Report category boundaries when continuous variables were categorized	
	(c) If relevant, consider translating estimates of relative risk into absolute risk for a	
	meaningful time period	
17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity	
	analyses	
18	Summarise key results with reference to study objectives	8
19	Discuss limitations of the study, taking into account sources of potential bias or	9-10
	imprecision. Discuss both direction and magnitude of any potential bias	
20	Give a cautious overall interpretation of results considering objectives, limitations,	10
	multiplicity of analyses, results from similar studies, and other relevant evidence	
21	Discuss the generalisability (external validity) of the study results	9-10
on		
22	Give the source of funding and the role of the funders for the present study and, if	14
		1
	14* 15* 16 17 18 19 20 21 on	eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Cobort study—Summarise follow-up time (eg, average and total amount) 15* Cobort study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers in each exposure category, or summary measures of exposure Cross-sectional study—Report numbers of outcome events or summary measures 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses 18 Summarise key results with reference to study objectives 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 21 Discuss the generalisability (external validity) of the study results

^{*}Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.